Inspire ends denufosol retinal program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inspire discontinues its Phase II pilot trials of the P2Y2 agonist denufosol (INS37217) for macular edema "and has no plans to conduct any further studies of denufosol for the treatment of retinal disease," the firm says Jan. 20. Data in two studies "did not demonstrate improvement in either reduction or retinal thickness or improvement in visual acuity." While the trials have been halted, Inspire will follow treated patients for one year. The company announced Jan. 30 that it is moving denufosol into Phase III for treatment of cystic fibrosis. Inspire has another P2Y2 agent, diquafosol, which is "approvable" for dry eye (1Pharmaceutical Approvals Monthly December 2005, p. 5)...
You may also be interested in...
Pfizer, Allergan And Schering NMEs Receive Second “Approvable” Letters
Pfizer’s anidulafungin received a second “approvable” letter Nov. 25 for treatment of esophageal candidiasis, FDA said.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.